Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves' orbital fibroblasts.

Abstract

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), along with its receptor fibroblast growth factor-inducible (Fn)14, is associated with various biological activities including inflammation. However, its role in the pathogenesis of Graves' orbitopathy (GO) is unknown. In this study, we investigated the mechanism by which TWEAK regulates inflammatory signaling in orbital fibroblasts from GO patients. We found that TWEAK and tumor necrosis factor-α (TNFA) mRNA levels were upregulated in GO as compared to non-GO tissue samples. TWEAK, TNF receptor (TNFR)1, TNFR2, and TNFR superfamily member 12A mRNA, and TWEAK and Fn14 protein levels were increased by interleukin (IL)-1β and TNF-α treatment. Treatment with exogenous recombinant TWEAK increased the transcript and protein expression of the pro-inflammatory cytokines IL-6, IL-8, and monocyte chemoattractant protein-1 to a greater extent in GO than in non-GO cells, while treatment with the anti-Fn14 antibody ITEM4 suppressed TWEAK-induced pro-inflammatory cytokine release and hyaluronan production. Additionally, the serum level of TWEAK was higher in Graves' disease patients with (341.86 ± 86.3 pg/ml) as compared to those without (294.09 ± 41.44 pg/ml) GO and healthy subjects (255.33 ± 39.38 pg/ml), and was positively correlated with clinical activity score (r = 0.629, P < 0.001) and thyroid binding immunoglobulin level (r = 0.659, P < 0.001). These results demonstrate that TWEAK/Fn14 signaling contributes to GO pathogenesis. Moreover, serum TWEAK level is a potential diagnostic biomarker for inflammatory GO, and modulating TWEAK activity may be an effective therapeutic strategy for suppressing inflammation and tissue remodeling in GO.

• Authors: Sung Jun Lee, Jinjoo Kim, JaeSang Ko, Eun Jig Lee, Hyoung Jun Koh, Jin Sook Yoon
• Journal: PloS one (PLoS One) Vol. 13 Issue 12 Pg. e0209583 ( 2018) ISSN: 1932-6203 [Electronic] United States
• PMID: 30576385 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• CCL2 protein, human
• Chemokine CCL2
• Cytokine TWEAK
• Interleukin-1beta
• Interleukin-6
• Interleukin-8
• Receptors, Tumor Necrosis Factor, Type I
• Receptors, Tumor Necrosis Factor, Type II
• TNFSF12 protein, human
• TWEAK Receptor
• Tumor Necrosis Factor-alpha

Topics

• Adult
• Apoptosis (genetics)
• Chemokine CCL2 (genetics)
• Cytokine TWEAK (blood, genetics)
• Female
• Fibroblasts (metabolism, pathology)
• Gene Expression Regulation (genetics)
• Graves Ophthalmopathy (blood, genetics, pathology)
• Humans
• Inflammation (blood, genetics, pathology)
• Interleukin-1beta (genetics)
• Interleukin-6 (genetics)
• Interleukin-8 (genetics)
• Male
• Middle Aged
• Receptors, Tumor Necrosis Factor, Type I (genetics)
• Receptors, Tumor Necrosis Factor, Type II (genetics)
• Signal Transduction (genetics)
• TWEAK Receptor (blood, genetics)
• Tumor Necrosis Factor-alpha (genetics)